

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1.-33. (Canceled)

34. (Currently amended) A chimeric polypeptide comprising the following components:

- (a) a streptokinase component capable of plasminogen activation; and
- (b) a fibrin-binding component, wherein said fibrin-binding component is fibrin-binding domains 4 and 5 of human fibronectin, or is fibrin-binding domains 1 and 2 of human fibronectin;

wherein said streptokinase component and said fibrin-binding component are fused via a peptide bond and are linked through a region that is sufficiently flexible so as to prevent activation of plasminogen by said streptokinase component, and so as to allow plasmin-dependent activation of said streptokinase component,

wherein said chimeric polypeptide is encoded by a polynucleotide selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

35.-52. (Canceled)

53. (New) A pharmaceutical composition comprising the chimeric polypeptide of claim 34, and a stabilizer.

AMENDMENT UNDER 37 CFR §1.116  
Appl No. 09/940,235

Attorney Docket Q89732

54. (New) The pharmaceutical composition of claim 53, wherein said stabilizer is human serum albumin or mannitol.